Telaprevir Experience From Turkey
| Author | Suheyla Komur | en |
| Author | Behice Kurtaran | en |
| Author | Ayse Seza Inal | en |
| Author | Husnu Pullukcu | en |
| Author | Aslihan Ulu | en |
| Author | Ferit Kuscu | en |
| Author | Tansu Yamazhan | en |
| Author | Yesim Tasova | en |
| Author | Hasan Salih Zeki Aksu | en |
| Orcid | Suheyla Komur [0000-0003-2414-559X] | en |
| Issued Date | 2015-02-28 | en |
| Abstract | Background: In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1. Objectives: In Turkey, telaprevir has been used since March 2013. We aimed to evaluate results of patients with chronic hepatitis C treated with telaprevir, peginterferon and ribavirin. Patients and Methods: We evaluated 28 patients with genotype 1 chronic hepatitis C infection treated with triple drug regimen containing telaprevir, in three medical centers in Turkey, retrospectively. Demographic data of patients, treatment indications, adverse events and outcomes were recorded. Results: Of 28 patients intended to treat, 25 (89.2%) patients completed the treatment. Overall, 21 (82.1%) patients had relapse and five patients were non-responder. Regarding the treatment outcomes of Telaprevir based regimen, 20/26 patients achieved sustained virological response. Pruritus, rash, dysgeusia, anorectal discomfort and anemia were main adverse effects. Blood transfusion and ribavirin dose reduction required for 7 and 11 patients, respectively. Due to several adverse effects, 10 patients were hospitalized. Conclusions: Although more frequent and severe adverse effects, telaprevir has been promising for patients with treatment-experienced hepatitis C. | en |
| DOI | https://doi.org/10.5812/hepatmon.25639 | en |
| Keyword | Genotype 1 | en |
| Keyword | Hepatitis C | en |
| Keyword | Telaprevir | en |
| Keyword | Turkey | en |
| Publisher | Brieflands | en |
| Title | Telaprevir Experience From Turkey | en |
| Type | Brief Report | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 15471-pdf.pdf
- Size:
- 59.55 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF